Medical Device Licence (MDL) Application Process

1. Key takeaways

The Medical Device Licence (MDL) application is submitted by the manufacturer. After Health Canada accepts the application, it first completes a screening step covering formal and compliance aspects, and only then moves into substantive review. Class III and Class IV applications must contain evidence of clinical effectiveness — the accepted forms include clinical trials, clinical reviews, meta-analyses and reviews of real-world evidence. An application that does not pass screening is returned, and the review stage can be extended when Health Canada issues a request for additional information. In practice, this means that the quality of the submission package, in the formal sense, has a direct bearing on how the process starts, while the depth of the clinical evidence determines what the substantive review will examine.

• The applicant for an MDL is the manufacturer, and the licence is held by that same entity throughout its validity.
• Screening takes place before review, so the completeness of the submission package is itself a gate that the application must clear.
• Evidence of clinical effectiveness is mandatory for Class III and Class IV applications; the official list names four accepted forms of such evidence.
• Class II, Class III or Class IV devices must not be sold or imported without a valid MDL in place.
• Application fees are set out in Schedule 8 of the fee order and are payable regardless of the outcome of the review.

2. Legal basis

The table below collects the primary regulatory sources for the MDL application process, including the provisions on licence applications and issuance, the requirement for clinical effectiveness evidence at the highest risk classes, the validity requirement for sale and import, and the current fee schedule for licence applications and amendment applications.

3. Expert insights

Insight 1: The clinical effectiveness threshold is set at Class III and IV.

Health Canada’s official wording is: “As Class III and IV medical devices pose the highest level of risk, applications for licensing must contain evidence of their clinical effectiveness.” The officially listed forms of evidence are four: clinical trials, clinical reviews, meta-analyses, and reviews of real-world evidence. This means that for Class III and Class IV devices, an approach that relies on an equivalence argument alone, in place of clinical evidence, is not an acceptable substitute under this requirement. The practical consequence is that the form of clinical evidence should be treated as a scoping decision made at the very beginning of the project, because that decision shapes the clinical work that follows and the way the clinical section of the dossier is written. Waiting until the technical documentation is complete before choosing the evidence form tends to create rework, since the evidence types differ in scope, in the sources they draw on, and in the way they must be presented to reviewers.

Insight 2: The existence of a screening step means that submission completeness is itself a gate.

An application must pass screening before it can enter review. Defects found at the screening stage — missing items, non-conforming formats, inconsistent numbering — lead to the application being returned or delayed, and these defects are unrelated to the technical quality of the product itself. This is precisely why dossier preparation should be organised as a standalone work package with its own internal checks. A technically strong submission can still fail at screening if the administrative layer around it is incomplete, and the time lost in such a case is time spent before any substantive assessment has even begun. Treating the formal layer as a distinct deliverable, with a review of its own, keeps this risk under control.

Insight 3: Fees are independent of the review outcome and are adjusted annually.

The MDL application fee is set out in Schedule 8 of the Order Respecting Fees for Drugs and Medical Devices, and the Health Canada fee page gives the amounts effective from 2026-04-01 as: Class II 643 CAD, Class III 14,163 CAD, Class IV 30,713 CAD. Payment of the fee is a precondition for the application to be processed, and it does not constitute any commitment with respect to the licensing outcome. Because the amounts are published on an annual cycle, a submission planned near the effective date of a new fee year should be checked against the rate in force at the moment of submission, so that the budget and the payment instruction remain aligned with the schedule actually applicable.

Insight 4: A licence is a continuous state, not a one-time acquisition.

Health Canada’s official wording uses the phrase “without a valid medical device licence”, where the operative word is valid. If a licence is suspended or cancelled, the eligibility to sell the device is interrupted at the same moment, because the sale and import prohibition attaches to the absence of a valid licence rather than to the absence of a licence that was once issued. This differs from the understanding that a licence, once obtained, remains permanently usable. It follows that the regulatory status of each licence should be part of routine monitoring, and not only a question asked at the time of the original application.

4. Practical recommendations

• For Class III and Class IV projects, determine the form of clinical evidence during dossier planning: select from the four officially listed forms and document the rationale for the choice.
• Treat passing screening as an independent first milestone, and do not postpone formal housekeeping in favour of polishing the technical sections of the dossier.
• Build the budget on the fee tiers effective from 2026-04-01: Class II 643, Class III 14,163, Class IV 30,713 CAD.
• If a submission is planned close to April 1, confirm the applicable annual fee rate according to the actual point in time at which the application is submitted.
• Bring licence validity into ongoing monitoring, rather than checking only whether a licence was once obtained.

5. Verification checklist

• □ The applicant has been confirmed to be the manufacturer
• □ For Class III / IV, one of the four forms of clinical effectiveness evidence has been prepared and the rationale for the choice has been documented
• □ A formal self-check against the screening requirements has been completed (missing items, format, numbering consistency)
• □ The budget has been prepared at the applicable annual fee rates (643 / 14,163 / 30,713 CAD)
• □ It has been confirmed that fee payment is unrelated to the licensing outcome
• □ A mechanism for ongoing monitoring of licence validity is in place

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com